Pro-Pharmaceuticals Announces Submission of Drug Master File for DAVANAT(R) to FDA (Business Wire)

yahoo.com     May 20, 2008            

NEWTON, Mass.----Pro-Pharmaceuticals, Inc. , a Company developing carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, has completed an important step toward submission of a New Drug Application for DAVANAT® by filing the Drug Master File to the U.S. [read full story]                

Full Coverage

Pro-Pharmaceuticals Receives Amex Non-Compliance Notice (Business Wire)

yahoo.com     May 20, 2008          

NEWTON, Mass.----Pro-Pharmaceuticals, Inc. , a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, today announced the American Stock Exchange notified the Company that it does not meet a continued listing standard because it has less...                

comments

Pro-Pharmaceuticals Announces Submission of Drug Master File for DAVANAT(R) to FDA

genengnews.com     May 21, 2008          

News source: Business Wire Pro-Pharmaceuticals, Inc. , a Company developing carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, has completed an important step toward submission of a New Drug Application (NDA) for DAVANAT(R) by filing the Drug Master File (DMF) to the...                

comments

Pro-Pharmaceuticals Receives Amex Non-Compliance Notice

genengnews.com     May 21, 2008          

News source: Business Wire Pro-Pharmaceuticals, Inc. , a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, today announced the American Stock Exchange ("Amex") notified the Company that it does not meet a continued listing standard...                

comments

                   

Pro-Pharmaceuticals Issues Letter to Shareholders (Business Wire)

yahoo.com     May 21, 2008          

Wednesday May 21, 7:00 am ET ), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has issued an open letter to shareholders from Theodore D. Zucconi, Ph.D., President of the Company. We have chosen to pursue a U.S. Food and Drug...                

comments

                   

Pro-Pharmaceuticals Issues Letter to Shareholders

redorbit.com     May 21, 2008          

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has issued an open letter to shareholders from Theodore D. Zucconi, Ph.D., President of the Company.                

comments

                   

Pro-Pharmaceuticals Issues Letter to Shareholders

genengnews.com     May 21, 2008          

News source: Business Wire Pro-Pharmaceuticals, Inc. , a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, has issued an open letter to shareholders from Theodore D. Zucconi, Ph.D., President of the Company. The most frequent...                

comments